Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study

Phase 2 study of pembrolizumab in patients with advanced rare cancers

(2020) Aung Naing et al.   Journal for ImmunoTherapy of Cancer

Immunotherapy in Corticotroph and Lactotroph Aggressive Tumors and Carcinomas: Two Case Reports and a Review of the Literature

(2020) Camille Duhamel et al.   Journal of Personalized Medicine

Stratifying nonfunctional pituitary adenomas into two groups distinguished by macrophage subtypes

(2019) Garima Yagnik et al.   Oncotarget

Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab

(2019) Mario Caccese et al.   ANTI-CANCER DRUGS

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

(2019) Aurelien Marabelle et al.   JOURNAL OF CLINICAL ONCOLOGY

Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens

(2018) Romualdo Barroso-Sousa et al.   JAMA Oncology

Marked response of a hypermutated adrenocorticotropic hormone-secreting pituitary carcinoma to ipilimumab and nivolumab

(2018) Andrew L Lin et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The natural course of hypermutator gliomas.

(2018) Carlos Kamiya-Matsuoka et al.   JOURNAL OF CLINICAL ONCOLOGY

European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas

(2017) Gerald Raverot et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab

(2017) Keiko Kitajima et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy

(2017) Tiffany R. Hodges et al.   NEURO-ONCOLOGY

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue

(2016) Marisa Dolled-Filhart et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors

(2016) Yu Mei et al.   Oncotarget

Eukaryotic Mismatch Repair in Relation to DNA Replication

(2015) Thomas A. Kunkel et al.   Annual Review of Genetics

Immune Cell Infiltrates in Pituitary Adenomas: More Macrophages in Larger Adenomas and More T Cells in Growth Hormone Adenomas

(2015) Jian-Qiang Lu et al.   ENDOCRINE PATHOLOGY

Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment

(2015) Mizuki Nishino et al.   EUROPEAN JOURNAL OF RADIOLOGY

Mutational landscape and significance across 12 major cancer types

(2013) Cyriac Kandoth et al.   NATURE

High Response Rates and Prolonged Survival in Patients With Corticotroph Pituitary Tumors and Refractory Cushing Disease From Capecitabine and Temozolomide (CAPTEM)

(2013) Brad E. Zacharia et al.   NEUROSURGERY

The epidemiology and genetics of pituitary adenomas

(2009) Adrian F. Daly et al.   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM